Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight. In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.

NCT Number	NCT07292441
Lead Sponsor	Gan & Lee Pharmaceuticals.
Conditions	Overweight or Obesity
Enrollment	500 participants
Start Date	2026-01-22
Primary Completion	2027-09 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-03-11